Sheila Kelly

903 total citations
17 papers, 553 citations indexed

About

Sheila Kelly is a scholar working on Rheumatology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Sheila Kelly has authored 17 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 6 papers in Pathology and Forensic Medicine and 5 papers in Hematology. Recurrent topics in Sheila Kelly's work include Rheumatoid Arthritis Research and Therapies (12 papers), Systemic Lupus Erythematosus Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Sheila Kelly is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (12 papers), Systemic Lupus Erythematosus Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Sheila Kelly collaborates with scholars based in United States, Germany and United Kingdom. Sheila Kelly's co-authors include Mark C. Genovese, Dafna D. Gladman, Paul P. Tak, Jean‐Claude Becker, Leonard H. Sigal, Philip J. Mease, Alan Kivitz, J. Wollenhaupt, Christopher T. Ritchlin and Leslie R. Harrold and has published in prestigious journals such as The Lancet, Seminars in Arthritis and Rheumatism and BMC Musculoskeletal Disorders.

In The Last Decade

Sheila Kelly

17 papers receiving 538 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheila Kelly United States 11 400 220 155 66 62 17 553
R Fleischmann United States 8 375 0.9× 213 1.0× 187 1.2× 59 0.9× 74 1.2× 29 674
C. Codding United States 5 445 1.1× 152 0.7× 188 1.2× 83 1.3× 83 1.3× 9 570
Rina Mina United States 12 496 1.2× 291 1.3× 151 1.0× 39 0.6× 79 1.3× 12 639
Riitta Koivuniemi Finland 14 260 0.7× 110 0.5× 74 0.5× 45 0.7× 57 0.9× 26 496
Ejaz Pathan United Kingdom 14 541 1.4× 369 1.7× 175 1.1× 49 0.7× 34 0.5× 28 737
Daniel Siri Argentina 4 517 1.3× 189 0.9× 253 1.6× 53 0.8× 72 1.2× 4 645
Marina Stanislav Russia 9 430 1.1× 192 0.9× 179 1.2× 84 1.3× 83 1.3× 20 601
Daisuke Hoshi Japan 15 586 1.5× 112 0.5× 177 1.1× 150 2.3× 57 0.9× 53 792
Christopher C. Striebich United States 10 361 0.9× 212 1.0× 74 0.5× 62 0.9× 178 2.9× 20 647
Arthur F. Kavanaugh United States 13 371 0.9× 377 1.7× 156 1.0× 36 0.5× 106 1.7× 20 689

Countries citing papers authored by Sheila Kelly

Since Specialization
Citations

This map shows the geographic impact of Sheila Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheila Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheila Kelly more than expected).

Fields of papers citing papers by Sheila Kelly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheila Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheila Kelly. The network helps show where Sheila Kelly may publish in the future.

Co-authorship network of co-authors of Sheila Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of Sheila Kelly. A scholar is included among the top collaborators of Sheila Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheila Kelly. Sheila Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Harrold, Leslie R., Sheila Kelly, Xue Han, et al.. (2024). Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive. Advances in Rheumatology. 64(1). 10–10. 1 indexed citations
2.
Harrold, Leslie R., Sheila Kelly, Xue Han, et al.. (2023). Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+. Rheumatology and Therapy. 10(3). 575–587. 1 indexed citations
3.
Sparks, Jeffrey A., Leslie R. Harrold, Teresa A. Simon, et al.. (2023). Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review. Seminars in Arthritis and Rheumatism. 62. 152249–152249. 16 indexed citations
4.
Harrold, Leslie R., Seán Connolly, Sheila Kelly, et al.. (2021). Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA. Rheumatology and Therapy. 9(2). 465–480. 16 indexed citations
5.
Harrold, Leslie R., Ying Shan, Sabrina Rebello, et al.. (2020). Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry. Rheumatology International. 40(8). 1239–1248. 6 indexed citations
6.
Harrold, Leslie R., Ying Shan, Sabrina Rebello, et al.. (2020). Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. Clinical Rheumatology. 39(6). 1899–1905. 26 indexed citations
7.
Harrold, Leslie R., Heather J. Litman, Seán Connolly, et al.. (2019). Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. Rheumatology and Therapy. 6(2). 217–230. 19 indexed citations
8.
Alemao, E., Heather J. Litman, Seán Connolly, et al.. (2018). Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. The Journal of Rheumatology. 45(10). 1353–1360. 2 indexed citations
9.
Harrold, Leslie R., Heather J. Litman, Seán Connolly, et al.. (2017). A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?. Clinical Rheumatology. 36(6). 1215–1220. 13 indexed citations
10.
Harrold, Leslie R., Heather J. Litman, Seán Connolly, et al.. (2017). Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. The Journal of Rheumatology. 45(1). 32–39. 39 indexed citations
11.
Bandyopadhyay, Somnath, Seán Connolly, Omar Jabado, et al.. (2017). Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Science & Medicine. 4(1). e000206–e000206. 10 indexed citations
12.
Alten, Rieke, Clifton O. Bingham, Stanley Cohen, et al.. (2016). Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskeletal Disorders. 17(1). 231–231. 50 indexed citations
13.
Ruderman, Eric, et al.. (2014). Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis. Rheumatology and Therapy. 1(1). 31–44. 8 indexed citations
14.
Weinblatt, Michael E., Larry W. Moreland, René Westhovens, et al.. (2013). Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program. The Journal of Rheumatology. 40(6). 787–797. 104 indexed citations
15.
Mease, Philip J., Mark C. Genovese, Alan Kivitz, et al.. (2010). Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial. Arthritis & Rheumatism. 63(4). 939–948. 230 indexed citations
16.
Kelly, Sheila, et al.. (2003). Myoclonic jerks associated with gabapentin. Palliative Medicine. 17(8). 717–718. 11 indexed citations
17.
Charlton, Anne, David While, & Sheila Kelly. (1998). Tobacco sponsorship of Formula One motor racing. The Lancet. 351(9100). 452–452. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R Fleischmann Breakdown of academic impact, for papers by C. Codding Breakdown of academic impact, for papers by Rina Mina Breakdown of academic impact, for papers by Riitta Koivuniemi Breakdown of academic impact, for papers by Ejaz Pathan Breakdown of academic impact, for papers by Daniel Siri Breakdown of academic impact, for papers by Marina Stanislav Breakdown of academic impact, for papers by Daisuke Hoshi Breakdown of academic impact, for papers by Christopher C. Striebich Breakdown of academic impact, for papers by Arthur F. Kavanaugh
Rankless by CCL
2026